Robert Klamroth
YOU?
Author Swipe
View article: European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice
European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice Open
Introduction Glanzmann's thrombasthenia is a rare inherited platelet disorder characterized by a lack of platelet aggregation. Patients tend to be diagnosed in early childhood with treatment strategies involving a multifaceted approach to …
View article: Triangulating data to define patient pathways, diagnostic and treatment patterns, and outcomes in cancer patients with deep vein thrombosis in Germany: a mixed-methods real-world data study
Triangulating data to define patient pathways, diagnostic and treatment patterns, and outcomes in cancer patients with deep vein thrombosis in Germany: a mixed-methods real-world data study Open
Purpose Cancer incidence is rising in Germany, increasing the burden of cancer-associated deep vein thrombosis (DVT). To improve prevention, diagnosis, and treatment, robust regional data on patient numbers, cancer types, healthcare access…
View article: Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A
Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A Open
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). Standard treatment involves immunosuppressive therapy (IST), which carries a significant risk of serio…
View article: Outcome of Surgical Interventions in Patients with Haemophilia A and B Treated with Extended Half-Life (EHL) Factor Concentrates in a Single Centre
Outcome of Surgical Interventions in Patients with Haemophilia A and B Treated with Extended Half-Life (EHL) Factor Concentrates in a Single Centre Open
The prevention of intraoperative bleeding in patients with haemophilia is the key to a successful surgical procedure. Daily life of patients with haemophilia A and B significantly improved with prophylaxis with extended half-life factor co…
View article: Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group
Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group Open
Background Following the approval of the first gene therapies for haemophilia, it is essential to develop an optimal infrastructure for the administration of gene therapy. This can be ensured by identifying the criteria for the definition …
View article: Epidemiology, Health Care Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Analysis of German Claims Data from 2016 to 2021
Epidemiology, Health Care Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Analysis of German Claims Data from 2016 to 2021 Open
In Germany, hemophilia patients with a severe bleeding phenotype receive lifelong prophylactic treatment with intravenous concentrated factor VIII (FVIII) or IX (FIX) to prevent bleeding events. To assess the economic value of emerging tre…
View article: Immune Tolerance Induction With a Recombinant Factor <scp>VIII</scp> Fc in Haemophilia A: Data From a Chart Review Study
Immune Tolerance Induction With a Recombinant Factor <span>VIII</span> Fc in Haemophilia A: Data From a Chart Review Study Open
Objective To report data from an ITI chart review study (NCT03951103) for first‐time and rescue ITI with recombinant factor VIII Fc fusion protein (rFVIIIFc) in persons with haemophilia A. Methods Retrospective and prospective real‐world d…
View article: Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies Open
Introduction The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention …
View article: Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study Open
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) e…
View article: A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis
A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis Open
Plain Language Summary: What is the study about? Hemophilia A is a genetic bleeding disorder that causes bleeding for long periods because of lower than normal levels of factor VIII (FVIII), a protein that is important for blood clotting. …
View article: Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease Open
Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management o…
View article: International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal Open
Introduction Evidence‐based clinical practice guidelines drive optimal patient care and facilitate access to high‐quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from randomi…
View article: Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren
Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren Open
Since the 1970s, specialized hemophilia centers have been established to optimize the complex and costly treatment of patients with severe bleeding disorders. In 2019, the first GTH guidelines on the structural and process quality of hemop…
View article: Danaparoid—Consensus Recommendations on Its Clinical Use
Danaparoid—Consensus Recommendations on Its Clinical Use Open
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. T…
View article: The Importance of Clinical Context and Consistency in Methodology When Using Matching-Adjusted Indirect Comparisons (MAICs) to Compare Outcomes
The Importance of Clinical Context and Consistency in Methodology When Using Matching-Adjusted Indirect Comparisons (MAICs) to Compare Outcomes Open
Hemophilia A is rare, which makes large, randomized, controlled, statistically driven, head-to-head comparison trials difficult. Matching-adjusted indirect comparisons (MAICs) are validated statistical tools designed to help make the resul…
View article: Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience Open
Dear Editor Valoctocogene roxaparvovec is a gene therapy that has been approved for the treatment of adults with severe haemophilia A since 2022 in Europe and 2023 in the USA.1, 2 It uses an adeno-associated virus serotype 5 to deliver a f…
View article: The association between unemployment and treatment among adults with hemophilia
The association between unemployment and treatment among adults with hemophilia Open
Our analysis suggests that by maintaining factor levels above a critical threshold (3%-5%), prophylactic treatment for people with hemophilia could help avoid unemployment due to disability. While prophylaxis is more costly and can be burd…
View article: Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A
Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A Open
Claims data are increasingly discussed to evaluate health care for rare diseases (resource consumption, outcomes and costs). Using haemophilia A (HA) as a use case, this analysis aimed to generate evidence for the aforementioned informatio…
View article: Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A Open
BackgroundAcquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) is standard of care to eradicate autoantibody production and protec…
View article: Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline Open
In the recently updated German S2k Guideline “Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism,” a new chapter was incorporated about recurrent venous thromboembolism (VTE) in patients on anticoagulation treatment. Despi…
View article: Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism Open
It is an honor and a great pleasure for us to be guest editors for this special issue of Hämostaseologie – Progress in Haemostasis, which addresses important issues surrounding the complex of venous thromboembolism (VTE). In February 2023,…
View article: Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline Open
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common manifestations of venous thromboembolism (VTE). Most DVTs affect the lower-extremity veins. Since the symptoms of DVT are non-specific, a prompt and standardised di…
View article: Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies
Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies Open
Introduction Over the last decades progress in haemophilia treatment has been remarkable and prophylaxis with clotting factor concentrates in haemophilia A and B has been established as the standard of care in individuals with haemophilia …